Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:

• Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00)
• Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46)
• Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40)
• Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26)
• Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55)
• Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39)

CME information and select publications

Featuring an interview with Dr Joshua Richter, including the following topics:

• Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00)
• Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18)
• Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53)
• Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40)
• Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34)
• Racial and ethnic disparities in the treatment of MM (32:09)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics:

• Introduction (0:00)
• Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40)
• Role of Immunotherapy in Intermediate-Stage HCC (17:02)
• First-Line Therapy for Advanced HCC (19:56)
• Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29)
• Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02)
• Potential Role of HER2-Targeted Therapy for BTCs (1:17:16)

CME information and select publications